| scholarly article | Q13442814 |
| P50 | author | Christopher Winrow | Q43195343 |
| P2093 | author name string | Anthony L Gotter | |
| John J Renger | |||
| Steven V Fox | |||
| Joanne Stevens | |||
| Pamela L Tannenbaum | |||
| Paul J Coleman | |||
| Susan L Garson | |||
| Georgia B McGaughey | |||
| George D Hartman | |||
| Wei Lemaire | |||
| Thomayant Prueksaritanont | |||
| Donghui Cui | |||
| Steven D Young | |||
| Christopher D Cox | |||
| Richard G Ball | |||
| David B Whitman | |||
| Michael J Bogusky | |||
| Duane R Reiss | |||
| Scott M Doran | |||
| Tamara D Cabalu | |||
| Joyce Stellabott | |||
| C Meacham Harrell | |||
| John D Schreier | |||
| Rodney A Bednar | |||
| Michael J Breslin | |||
| P2860 | cites work | Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior | Q24315738 |
| The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity | Q24317782 | ||
| Orexin receptors: pharmacology and therapeutic opportunities | Q24597418 | ||
| A short history of SHELX | Q25938995 | ||
| The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene | Q28142783 | ||
| Diagnosis and treatment of chronic insomnia: a review | Q28237993 | ||
| Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation | Q29615680 | ||
| Reduced number of hypocretin neurons in human narcolepsy | Q33923479 | ||
| Promotion of sleep by targeting the orexin system in rats, dogs and humans | Q34607196 | ||
| Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia | Q34620802 | ||
| Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist | Q34628298 | ||
| Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. | Q34730569 | ||
| Insomnia causes, consequences, and therapeutics: an overview. | Q35602304 | ||
| Insomnia in the elderly: cause, approach, and treatment | Q36496339 | ||
| Comparative tolerability of newer agents for insomnia | Q37577869 | ||
| Orexin receptor antagonists: a review of promising compounds patented since 2006. | Q37697791 | ||
| Orexin receptor antagonists: a new concept in CNS disorders? | Q37764786 | ||
| Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia | Q37831916 | ||
| Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. | Q42727844 | ||
| Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. | Q42977303 | ||
| Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists. | Q43140905 | ||
| Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. | Q46024144 | ||
| Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding | Q47907189 | ||
| Diurnal variation in CSF orexin-A in healthy male subjects. | Q48508369 | ||
| Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. | Q48604068 | ||
| Allylic strain in six-membered rings | Q56680589 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 415-24, 337 | |
| P577 | publication date | 2012-02-03 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties | |
| P478 | volume | 7 |
| Q37220464 | A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia |
| Q92148238 | Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis |
| Q89484077 | Conformational ensemble comparison for small molecules in drug discovery |
| Q90978457 | Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists |
| Q37522859 | Discovery and development of orexin receptor antagonists as therapeutics for insomnia |
| Q28304842 | Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia |
| Q47839193 | Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach |
| Q27300998 | Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone |
| Q38108972 | Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders |
| Q38031982 | Emerging treatment for chronic migraine and refractory chronic migraine. |
| Q59082074 | Iron-catalysed tritiation of pharmaceuticals |
| Q41998350 | Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors |
| Q37427713 | Ligand-accelerated ortho-C-H alkylation of arylcarboxylic acids using alkyl boron reagents |
| Q60938770 | Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness |
| Q90636795 | Optical probing of orexin/hypocretin receptor antagonists |
| Q39026714 | Orexin OX2 Receptor Antagonists as Sleep Aids |
| Q59201264 | Orexin Receptor Antagonists |
| Q30437151 | Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs |
| Q48020552 | Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition |
| Q38269308 | Orexin receptor antagonists--a patent review (2010 to August 2014). |
| Q47718610 | Orexin research: patent news from 2016. |
| Q38221344 | Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? |
| Q48689667 | Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. |
| Q38743165 | Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder |
| Q35024529 | Profound methyl effects in drug discovery and a call for new C-H methylation reactions |
| Q37235803 | Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats |
| Q41961153 | Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs |
| Q42704416 | Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist |
| Q34443676 | Suvorexant for the treatment of insomnia |
| Q34975026 | The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold |
| Q37535058 | The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats |
| Q38231949 | The hypocretin/orexin system: an increasingly important role in neuropsychiatry. |
| Q36923729 | The hypocretins and the reward function: what have we learned so far? |
| Q99554949 | The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders |
| Q48226532 | Update on emerging drugs for insomnia |
Search more.